Fresh analysis suggests that individuals who stop using new GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass much more quickly than those who stop traditional diet and exercise programs.
Published data in a major health publication points out that while overweight individuals frequently drop a large proportion of their body weight while on the medication, the mass comes back at an average rate of nearly a kilo each month once they quit.
"Individuals purchasing these drugs must be cognizant of the risk of quick weight regain when the therapy is stopped," stated researcher Dr. Susan Jebb.
That rate of recovery implies a reversion to pre-treatment weight in about one and a half years.
Comparing Treatments
The analysis, which reviewed dozens of trials involving over 9,000 of patients, contrasted the results of these new drugs with conventional dieting.
Scientists point out that people who lose weight through dieting typically see a less rapid creep back—approximately 0.1 kg a month—after stopping.
Explaining the Quick Rebound
Doctors believe the way of the drugs explains the amplified rebound.
These medications mimic a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.
"Artificially providing the hormone concentrations far above than normal could lead to the system to produce less of its own natural GLP-1, and could diminish responsiveness to its actions," noted Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this GLP-1 'fix' results in appetite is no longer kept in check, making excessive eating far more likely."
A Lifelong Disease?
The NHS advise the jabs for people with weight-linked medical conditions, alongside recommended diet and exercise modifications.
Many experts contend that, given the significant potential of relapse, the treatment might need to be ongoing.
This view is reinforced by drug manufacturers, who state that the results "underscore the long-term nature of obesity," akin to managing diseases like hypertension.
User Accounts
People who have discontinued the jabs explain a intense resurgence of appetite.
"It was like a switch flipping and I was suddenly extremely hungry," described one woman.
This difficulty is worsened if users have not adopted sustainable lifestyle or habit modifications during treatment.
Growing Interest
Figures indicate that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with desire continuing to grow.
- Adoption is more common among women than men.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion access the drugs through private prescriptions rather than public health services.
Finally, researchers emphasize that while GLP-1 drugs are potent tools for shedding pounds, they are not a magic cure and maintained weight loss hinges on integrated behavioural support.
